Condition

Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

ClinicalTrials.gov condition label

Clinical trials1

Recruiting0

Common interventions1

Lead sponsors shown1

Clinical trials

1 shown

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain MetastasesNCT04339829 · 2020-08-01

UNKNOWN

Common interventions

DacomitinibDRUG1

Leading sponsors

Guangdong Association of Clinical Trials1

Trial status mix

UNKNOWN1

Phase mix

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.